MedTrace Logo

A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

NCT04683406 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2023-06-27

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, and active controlled clinical trial to assess the efficacy and safety of ZSP1273 tablets in the treatment of Acute Uncomplicated influenza A.

Conditions

Interventions

DRUG

ZSP1273 600 mg

3 X 200-mg tablet taken orally

DRUG

Placebo to Oseltamivir

Placebo capsules matching oseltamivir2 X 75-mg

DRUG

Oseltamivir(oral)

2 X 75-mg tablet taken orally

DRUG

Placebo to ZSP1273

Placebo capsules matching ZSP1273 600 mg

Sponsors & Collaborators

  • Guangdong Raynovent Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-28
Primary Completion
2023-04-01
Completion
2023-05-16

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04683406 on ClinicalTrials.gov